Sinotherapeutics, Inc.SSE: 688247

Report for Q3 2025

Oct 31, 2025 · Issued by Sinotherapeutics, Inc. via Shanghai Stock Exchange

Filed with SSE · Oct 31, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-789

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Sinotherapeutics, Inc. on 6ix

Earlier from Sinotherapeutics

Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Centralized Drug ProcurementOct 30, 2025
Indicative Announcement on Equity Change of Shareholding Reduction by Shareholder with Over 5% Shares to Less than 5%Oct 23, 2025
Announcement on Changing Signatory Certified Public AccountantOct 22, 2025
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Sitagliptin and Metformin Hydrochloride Sustained-release TabletsOct 21, 2025
Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% SharesOct 17, 2025

Later from Sinotherapeutics

All Sinotherapeutics news releases

Follow Sinotherapeutics into a list and get an email when it puts out news.

Follow Sinotherapeutics